Specify a stock or a cryptocurrency in the search bar to get a summary
RegenETP Inc.
RGTPQRegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. The company was formerly known as PolarityTE, Inc. and changed its name to RegenETP, Inc. in August 2023. RegenETP, Inc. is headquartered in Salt Lake City, Utah. Address: 1960 South 4250 West, Salt Lake City, UT, United States, 84104
Analytics
WallStreet Target Price
0.8 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RGTPQ
Dividend Analytics RGTPQ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RGTPQ
Stock Valuation RGTPQ
Financials RGTPQ
Results | 2019 | Dynamics |